Graphite Bio, Inc. (GRPH)

Market Cap	142.50M
Revenue (ttm)	n/a
Net Income (ttm)	-101.05M
Shares Out	58.16M
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,977
Open	2.32
Previous Close	2.32
Day's Range	2.32 - 2.45
52-Week Range	1.59 - 5.73
Beta	n/a
Analysts	Sell
Price Target	3.74 (+52.65%)
Earnings Date	May 11, 2023

About GRPH

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 114
• Stock Exchange: NASDAQ
• Ticker Symbol: GRPH

Analyst Forecast

According to 13 analysts, the average rating for GRPH stock is "Sell." The 12-month stock price forecast is $3.74, which is an increase of 52.65% from the latest price.

Price Target

$3.74

(52.65% upside)

Analyst Consensus: Sell